Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Risk Factors for 30-Day Readmission in Adults with Sickle Cell DiseaseBACKGROUND: Readmission to the hospital...
-
‘Every Time It’s A Battle’: In Excruciating Pain, Sickle Cell Patients Are Shunted AsideAmy Mason had toughed it out for hours o...
-
A Health Note From Dr. Biree Andemariam, SCDAA Chief Medical OfficerWhat You Need to Know About the Coronavi...
-
International Association of Sickle Cell Nurses and Professional AssociatesThe International Association of Sickle ...
-
Patient controlled analgesia for adults with sickle cell disease awaiting admission from the emergency departmentBackground: A treatment algorithm for s...
-
IASCNAPA Sickle Cell Disease Conference: Treating the Whole PersonDate: April 14-15, 2021 Place: Online/V...
-
Carolyn Rowley, PhDDr. Rowley is the Founder and Executive ...
